Blog
Welcome to our blog! Explore educational content ranging from innovative treatments to insightful medical knowledge, curated by Dr. Rezaian, a specialist in Rheumatology and Internal Medicine.
How Anti-SSa and Ro52 Shape the Future of Interstitial Lung Disease (ILD) in Myositis Patients
This study explores whether the presence of certain antibodies (anti-SSa and Ro52) affects the progression of lung disease (interstitial lung disease or ILD) in people with idiopathic inflammatory myopathies (IIM). These antibodies are often found in individuals with...
Breathing Easier: How Nintedanib Combats Lung Damage in Connective Tissue Disease
This study focuses on a treatment for patients with connective tissue diseases (CTD) who also have a lung condition called interstitial lung disease (ILD). This condition, when it becomes progressive and fibrosing (PF-ILD), can lead to serious lung damage. The...
Under the Radar: Severe Pancreatic Damage in IgG4-Related Disease
This study looked at a disease called IgG4-related disease (IgG4-RD), which is a condition where the immune system attacks various organs, leading to inflammation and damage. One of the most common places this happens is in the pancreas, which is known as autoimmune...
Breathing Uneasy: High Rates of Hidden Lung Issues in Newly Diagnosed Arthritis
Background and Purpose: Pulmonary issues are common yet often overlooked in people with rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA). These lung problems can lead to severe health consequences if...
Hydroxychloroquine: A Shield Against Fatty Liver Disease in Rheumatoid Arthritis Patients
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and can lead to various other health issues. Previous research has indicated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in RA patients. There’s a...
New Study Links Biologics to Lower Heart Disease Risk in RA
Background: Rheumatoid arthritis (RA) patients often face higher cardiovascular risks due to chronic inflammation. Biologic disease-modifying antirheumatic drugs (biologic drugs) help control this inflammation, especially in those who don’t respond well to...
Enhancing Arthritis Prediction: The Promise of anti-CCP3 Testing
Background: The study aimed to determine if testing for anti-CCP3 antibodies in patients who are negative for anti-CCP2 antibodies but have musculoskeletal symptoms could better predict the progression to inflammatory arthritis (IA) or rheumatoid arthritis (RA)....
TNFi Resistance in Juvenile Arthritis: Identifying the High-Risk Factors
This study investigated why some children with juvenile spondyloarthritis (JSpA) do not respond to TNF inhibitors (TNFi), a common treatment. Researchers analyzed data from patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)...
Gender-Specific Insights into Axial Juvenile Spondyloarthritis: What the Data Reveals
Background/Purpose: The study explores the differences between males and females with axial juvenile spondyloarthritis (axJSpA), a type of juvenile inflammatory arthritis. The goal was to understand if there are distinct clinical and imaging features based on sex....
Exploring High-Dose Etanercept for Juvenile Arthritis: Does More Mean Better?
Background: Juvenile idiopathic arthritis (JIA) is a condition in children causing joint inflammation. Etanercept is a common medication for JIA, but the best dose for effectiveness is unclear. This study looks at whether increasing the dose of etanercept helps...
Meet The Author
M M Rezaian, MD
Rheumatology
Dr. Rezaian, who has dedicated over thirty years to the practice of Rheumatology, focuses on the utilization of biologic therapies for treating rheumatic diseases, the study of Spondyloarthropathy, and the innovative field of Telemedicine. He is connected with the WVU Berkeley Medical Center in Martinsburg, West Virginia.